Sana Biotechnology (NASDAQ:SANA) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Sana Biotechnology (NASDAQ:SANA) announced its earnings results on Monday. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.02, Zacks reports.

Sana Biotechnology Stock Down 20.4 %

Sana Biotechnology stock traded down $0.57 during trading on Tuesday, hitting $2.21. The stock had a trading volume of 4,141,151 shares, compared to its average volume of 2,987,484. The stock’s 50 day moving average is $3.05 and its two-hundred day moving average is $3.23. Sana Biotechnology has a 1 year low of $1.52 and a 1 year high of $10.50. The stock has a market cap of $492.31 million, a price-to-earnings ratio of -1.56 and a beta of 1.63.

Insider Buying and Selling at Sana Biotechnology

In other news, insider Fmr Llc sold 290,912 shares of the company’s stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the transaction, the insider now owns 4,541,511 shares of the company’s stock, valued at approximately $29,474,406.39. This represents a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 31.10% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Jefferies Financial Group began coverage on Sana Biotechnology in a research report on Friday. They issued a “buy” rating and a $7.00 price objective for the company. TD Cowen raised Sana Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday, January 8th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Sana Biotechnology in a research report on Tuesday. Finally, Citizens Jmp raised Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 target price for the company in a research report on Tuesday. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Sana Biotechnology has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.